Relay Therapeutics, Inc. Common Stock Wells Fargo 21st Annual Healthcare Conference

Thanks so much. Thank you for having us.

Yeah, great to be here.

Thanks again for having us. Great to be here. Great way to kick off the fall season. Over the next 12 months, coming off a very exciting first 9 months of the year for us, made a number of disclosures across both vascular anomalies and breast cancer. We're able to fortify the balance sheet. Now as we look forward, we're really moving into the next leg of growth here as we start preparing to become a commercial company. I think a lot of that will be underpinned by additional disclosures and clarity on the regulatory path forward in both breast cancer and VAs. Specifically, we've guided to regulatory updates for both frontline breast cancer, a phase III trial, which we intend to start early next year.

We will go have a regulatory interaction before the end of this year and report back out on how that goes. Similarly, with vascular anomalies, that program is going quite well and quite fast from a development perspective. We will have a conversation with the agency on a potential accelerated approval path before the end of the year and report back out on that. From a data perspective, we will share additional vascular anomalies data before the end of the year, and we will share additional phase I/II triplet data in the first half of next year. So continues to be a very robust set of months for us before we get to the end of the year. Then moving our way quickly towards registrational readouts in both breast cancer and vascular anomalies.

Yeah. So we'll start with the second line because that's where we've got our current phase III running. The goal with zovegalisib when we set out was really to try and design a drug that was very specific and did not have the limitations of the generations that came before it, and so avoided some of the off-target toxicity. We went after the second line breast cancer population first because that was the biggest unmet need and the place where it made sense to start. What we were able to show, and Pete alluded to this earlier this year, we showed fed data.

We showed that we had an 11-month PFS, which was really exciting because it avoided some of the off-target toxicity, had a much cleaner profile, and it delivered against this promise of, if you could have a better tolerability profile, you should be able to extend the efficacy. That compares really nicely to capivasertib's 5.5 months in a post CDK4/6 setting. So we're really excited about that, and that's what gave us confidence to launch our second line phase III, which we started last year. Then earlier this year, we showed data from a median third-line population in the triplet setting also that Pete alluded to, and that looked really compelling both from an early efficacy perspective, we showed an ORR of 44% there.

But more importantly, we wanted to show that from a combinability perspective, it would be a really nice tolerable regimen for patients in the front line and could compete well with the existing standard of care.

Yeah. I think this is probably one of the most important priorities for us as a company right now. And it's going really well. It's a very compelling study for physicians and patients, given that you are taking zovegalisib plus fulvestrant versus capivasertib, the market leader right now, versus fulvestrant. People are very excited about it, and enrollment's going well. As Pete mentioned, we'll guide before the end of the year as to when last patient in will be. But right now, we're feeling really good about it, and we think that we will do very well compared to benchmarks that we've seen for similarly sized studies.

No, not at all. I think for us, it's one of the key priorities, as I mentioned. It's really important in terms of the patient population. There's a lot of excitement, we will have a completely separate team working on standing up the frontline study.